TransCode Therapeutics announced that it has been awarded a $2 million Direct to Phase II Small Business Innovation Research, SBIR, grant from the National Institutes of Health, NIH, to support clinical evaluation of TTX-MC138, TransCode’s lead therapeutic candidate. TransCode has recently activated three clinical trial sites to conduct a Phase I/II clinical trial of TTX-MC138 for the treatment of advanced solid tumors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAZ:
- TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
- Transcode Therapeutics announces Phase 1 trial initiation
- TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
- TransCode Therapeutics, Inc. Announces Closing of Public Offering
- Transcode Therapeutics 10M share Spot Secondary priced at 30c